文献速递类风湿关节炎系统性红斑狼疮其他结缔组织病

儿童风湿病生物制剂治疗25年:预后进展与持续挑战

25 Years of Biologics for the Treatment of Pediatric Rheumatic Disease: Advances in Prognosis and Ongoing Challenges.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2025-01-30

本文综述了过去25年儿童风湿病(PRD)生物制剂及靶向合成改善病情抗风湿药(bDMARD/tsDMARD)的治疗进展:依那西普1999年获批治疗幼年特发性关节炎(JIA)后,多种bDMARD和tsDMARD获批使JIA预后明显改善;但儿童起病系统性红斑狼疮(cSLE)仅有一种bDMARD获批,幼年皮肌炎(JDM)尚无获批药物,缺乏获批治疗方案仍是所有PRD的核心挑战。

要点

  • 依那西普1999年成为首个获批治疗JIA的生物制剂,此后多种bDMARD和tsDMARD获批使JIA预后明显改善。
  • cSLE仅有一种bDMARD获批,JDM尚无任何获批生物制剂。
  • 缺乏具有既定给药方案及已知疗效和安全性的获批治疗选择,仍是所有PRD包括自身炎症性疾病及其并发症的核心挑战。

核心结论

  • JIA领域多种bDMARD和tsDMARD获批后患者预后明显改善,而cSLE仅一种bDMARD获批、JDM无获批药物,缺乏获批治疗方案仍是所有PRD的核心挑战。

研究设计与样本

  • 综述:概述用于JIA各亚型的bDMARD和tsDMARD治疗研究,汇总其他PRD的bDMARD研究信息并聚焦导致监管批准的关键试验,同时总结bDMARD研究及PRD患者药物批准的当前监管格局。

主要发现

  • 美国有超过100种风湿病、约30万名儿童患有儿童风湿病(PRD),最常见者为JIA、cSLE和JDM。
  • 依那西普是首个获批治疗JIA的生物制剂,获批于1999年。
  • 此后其他阻断相关免疫通路的bDMARD和tsDMARD获批用于JIA治疗,使疾病预后明显改善。
  • cSLE仅有一种bDMARD获批,JDM则无任何bDMARD获批。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

There are over 100 rheumatic diseases and approximately 300,000 children with a pediatric rheumatic disease (PRD) in the United States. The most common PRDs are juvenile idiopathic arthritis (JIA), childhood-onset systemic lupus erythematosus (cSLE), and juvenile dermatomyositis (JDM). Effective and safe medications are essential because there are generally no cures for these conditions. Etanercept was the first biologic therapy for the treatment of JIA, approved in 1999. Since then, other biologic disease-modifying antirheumatic drugs (bDMARDs) and targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs) blocking relevant immunologic pathways have been approved for the treatment of JIA, resulting in a marked improvement of disease prognosis. Conversely, there is only one bDMARD that has been approved for cSLE, but none are approved for the treatment of JDM. Lack of approved therapeutic options, with established dosing regimens and known efficacy and safety, remains a central challenge in the treatment of all PRDs, including autoinflammatory diseases, and for complications of PRDs. This review provides an overview of bDMARD and tsDMARD treatments studied for the treatment of various subtypes of JIA, summarizes information from bDMARD studies in other PRDs, with a focus on pivotal trials that led to regulatory approvals, and highlights improved outcomes in patients with JIA with the reception of these newer medications. Further, we outline barriers and challenges in the treatment of other PRDs. Last, we summarize the current regulatory landscape for bDMARD studies and medication approvals for patients with PRDs.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Shishov M, Weiss PF, Levy DM, et al. 25 Years of Biologics for the Treatment of Pediatric Rheumatic Disease: Advances in Prognosis and Ongoing Challenges. Arthritis Care Res (Hoboken). 2025. PMID: 39651592. doi:10.1002/acr.25482

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。